What is GERN stock price today?

GERN (Geron Corp) stock is trading at $1.66 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is GERN stock going up or down today?

GERN stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy GERN stock now?

The decision to buy GERN depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is GERN a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for GERN based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is GERN stock overvalued or undervalued?

Use our DCF valuation calculator to determine if GERN is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is GERN's P/E ratio?

P/E ratio data for GERN will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is GERN's market cap?

GERN (Geron Corp) has a market capitalization of $1.06 billion, making it a small-cap stock.

What is GERN's price to book ratio?

GERN trades at a price-to-book (P/B) ratio of 4.69, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does GERN pay dividends?

GERN does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is GERN's dividend yield?

GERN does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is GERN stock a good long-term investment?

GERN's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is GERN's revenue growth rate?

GERN has shown revenue growth of 0.0% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

GERN is currently operating at a loss. Some companies prioritize growth over profitability in early stages. Review our financial analysis for detailed insights.

What are the risks of investing in GERN?

Key risks for GERN include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does GERN compare to its competitors?

Compare GERN to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize GERN's performance and positioning.

What is GERN's stock price target for 2026?

Our AI model provides price targets for GERN based on fundamental analysis: Bull case $2.16 (+30%), Base case $1.91 (+15%), Bear case $1.49 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about GERN?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for GERN. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is GERN's next earnings report?

GERN reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

GERN - Geron Corp

NYSE * Health Care * Biotechnology

$1.66

+$0.00 (+0.00%)

About Geron Corp

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

GERN Key Statistics

Market Cap

$1.06B

P/B Ratio

4.69

EPS

$-0.13

Revenue Growth

+0.0%

Profit Margin

-0.5%

Employees

258

How GERN Compares to Peers

GERN is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
GERN(This stock)	$1.06B	N/A	0%	-0.5%	-
AMGNAmgen Inc	$190.44B	24.8	0%	0.2%	vs AMGN
GILDGilead Sciences	$174.14B	20.7	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$113.60B	29.2	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$82.17B	18.7	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.03B	20.2	-0%	0.1%	vs BIIB

Geron Corp Company Information

Headquarters: California; U.S.A
Website: www.geron.com
Sector: Health Care
Industry: Biotechnology

GERN - Geron Corp

About Geron Corp

GERN Key Statistics

How GERN Compares to Peers

Geron Corp Company Information

GERN Lician Score

GERN Financial Snowflake

Upcoming Events for GERN